NuPathe dives on US FDA rejection of sumatriptan migraine patch
This article was originally published in Scrip
Executive Summary
NuPathe shares lost nearly half their value in morning trading on 30 August after the company disclosed that its new drug application (NDA) for its transdermal sumatriptan migraine patch Zelrix (NP101) had been rejected by the US FDA, which raised concerns about the safety of the drug.